AbbVie Inc.
Process for Manufacturing Pibrentasvir Active Drug Substance

Last updated:

Abstract:

The present invention relates to compositions of pibrentasvir, drug products thereof, and processes and intermediates for the preparation thereof. This invention relates to the drug product, active drug substance, intermediates, and processes of pibrentasvir, a NS5A inhibitor that is useful in the treatment of hepatitis C.

Status:
Application
Type:

Utility

Filling date:

29 Aug 2019

Issue date:

10 Jun 2021